Clostridium Infections Clinical Trial
Official title:
Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes
The purpose of the study is to establish the clinical disease outcomes and features of CDAD
associated with variant tcdC genotypes. Two hypotheses are to be tested in this study:
1. Severe CDAD and tcdC truncation:
Severe CDAD (defined by death and/or colectomy or secondary endpoints) is associated
with severe truncations (> 6 amino acid residues) in TcdC, a negative regulator of
toxin A/B production.
2. Disease in low risk populations (patients never exposed to health care facilities
and/or patients who never received antibiotics) of any severity is attributable to
strains of C. difficile with severe tcdC truncation.
The following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), date of specimen collection, presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 6 months of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, past medical history and outcomes. We will collect information retrospectively. ;
Observational Model: Case Control, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04179201 -
Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease
|
||
Completed |
NCT02563106 -
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
|
Phase 2 | |
Completed |
NCT00214461 -
Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers
|
Phase 1 | |
Completed |
NCT00314951 -
Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
|
Phase 3 | |
Completed |
NCT00328263 -
Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
|
Phase 3 | |
Completed |
NCT00127803 -
Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT00350298 -
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
|
Phase 2 | |
Withdrawn |
NCT05077085 -
Bezlotoxumab Versus FMT for Multiple Recurrent CDI
|
Phase 4 | |
Recruiting |
NCT02681068 -
MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation
|
N/A | |
Terminated |
NCT00384527 -
Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
|
Phase 3 | |
Completed |
NCT00269399 -
A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
|
Phase 3 | |
Completed |
NCT04026009 -
Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
|
Phase 1 | |
Recruiting |
NCT06277999 -
C.Difficile Observational Study
|
||
Completed |
NCT00468728 -
PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
|
Phase 3 |